Research Article
Formulation Development and Stability Studies of Norfloxacin Extended-Release Matrix Tablets
Table 4
Difference factor (
) and similarity factor (
) calculated for uncoated and coated norfloxacin matrix tablets.
| | Formulation | | |
| | HPMC K100LV 20% | 5.47 | 71.72 | | HPMC K100LV 30% | 8.50 | 62.32 | | HPMC K4M 20% | 9.22 | 70.03 | | HPMC K4M 30% | 14.23 | 66.36 | | PEO N60K 20% | 13.77 | 56.35 | | PEO N60K 30% | 14.66 | 57.81 | | PEO 301 20% | 2.00 | 91.85 | | PEO 301 30% | 3.12 | 88.95 |
|
|
